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Are you feeling overweight? Is your hairline receding? Maybe Meridia and Propecia are the answer for you!
Too embarrassed to go to the doctor? Too busy to go to the doctor? Too busy to stand in line at a pharmacy?
No problem. With the click of your mouse and a credit card number, you can order pharmaceuticals over the
Internet and have them delivered to your door...
Internet pharmacies are a relatively recent phenomenon. In January 1999, the Internet hosted about 30
Internet pharmacies, and by July of that year, over 400 such pharmacies had appeared.1 Today, the number
of Internet pharmacies may be as high as 1,000.2 Unfortunately, the actual number of Internet pharmacies
is unknown due to the anonymity of the Internet. Internet addresses can be easily created or removed, and
1Internet Pharmacies: Adding Disclosure Requirements Would Aid State and Federal Oversight, GAO Report to Con-
gressional Requesters, at 3 (October 2000) [Hereinafter GAO Report].
2Skidmore, Sarah, Oﬃcials Warn Those Ordering Prescription Drugs Online, The Florida Times, February 13, 2001, at
F-1.
1many Internet pharmacies use multiple web sites or portals to attract customers.3 Despite the diﬃculty in
counting Internet pharmacies, the real number can be expected to increase due to the proﬁt opportunities
in the pharmaceutical market. Internet pharmacies generated over $100 million in sales in 1999, and experts
predict that sales will reach $1 billion in 2002 and reach $15 billion by 2004.4
Internet pharmacies do oﬀer many beneﬁts to U.S. consumers. These beneﬁts include access to drugs for
the disabled, for whom a trip to a traditional pharmacy is diﬃcult; the ability to shop 24 hours a day; and
privacy for those who don’t feel comfortable discussing their medical conditions in public. The online option
can be cheaper since it eliminates several layers of overhead. Indeed, some legitimate Internet pharmacies
are selling prescription drugs online for up to 30% less than what is charged at traditional pharmacies.5
Besides added convenience and lower costs, Internet pharmacies can increase consumer access to relevant
medical information. Hyperlinks from Internet pharmacy webpages can provide customers with references
from other sources much more easily than a traditional pharmacy.
With all these beneﬁts, some may view the expected growth in Internet pharmacies to be positive revolution
for the healthcare industry. But embracing the growth of Internet pharmacies without immediately and
thoroughly addressing regulatory loopholes in the state and federal laws which apply to Internet pharmacies
could have terrible consequences for the health of the American public. Internet pharmacies should not be
regulated (or free from heavy regulation) like other forms of e-commerce since improperly dispensed medi-
cations could cause drug interactions, allergic reactions, and even death.
3GAO Report, supra note 1, at 10.
4Chambliss, Lauren, Rogue Online Drugs Sales are Not What the Doctor Ordered, Evening Standard, March 11, 2002, at
41.
5Dana, Miller, Trends in Self-Care, Patient Care, August 15, 2000, at 57.
2This paper will analyze the growing problem “rogue” Internet pharmacies—Internet pharmacies that con-
duct illegal or unsafe prescribing and dispensing practices that endanger the health of the customers they
serve. Section I will describe the diﬀerent categories of Internet pharmacies and distinguish the practice of
legitimate Internet pharmacies from those of rogue Internet pharmacies. Section II will discuss the dangers
customers face by ordering from rogue Internet pharmacies. Section III will address the currently regu-
latory regime for domestic Internet pharmacies. Section IV will address the currently regulatory regime
for foreign Internet pharmacies. Finally, Section V will analyze recent proposals to more eﬀectively curtail
the illegal practice of domestic and foreign Internet pharmacies.
I. Types of Internet Pharmacies.
There are four basic categories of online pharmacies that cater to American consumers. The focus of
this paper will be on the rogue Internet pharmacies, which encompass the last three categories of online
pharmacies. Some estimate that rogue sellers outnumbers legitimate Internet pharmacies by a ratio of over
60 to 1.6
Type 1: Legitimate. Many companies have established “legitimate Internet pharmacies.” These businesses
are located in the United States. They require the consumer to obtain and submit a prescription from
a licensed physician. The consumer can transfer a prescription from another pharmacy, mail in a new
prescription, or have his physician submit the prescription by fax or telephone. Before dispensing any drugs,
the Internet pharmacy veriﬁes that a licensed physician has actually issued the prescription. These types
of Internet pharmacies operate similar to traditional pharmacies, and many are extensions of traditional,
brick-and-mortar pharmacies.7 Thus, these types of sites are not controversial.
6Otrompke, John. Internet Likely to Open Brave New World in Global Pharmaceuticals Trade, Medicine & Health,
October 9, 2000, at S1.
7GAO Report, supra note 1, at 10.
3Type 2: Borderline-Foreign. Some Internet pharmacies operate in certain foreign countries, particularly
Canada, with regulations on distribution of pharmaceuticals that are similar to those in the U.S. These sites
require customers to submit a U.S. doctor’s prescription and ﬁll out a basic questionnaire. After a Canadian
doctor reviews the information, he may then write a Canadian prescription for the same medication and
dose. The Internet pharmacy then ﬁlls the order and ships it to the consumer.8 Although these practices
are permitted under Canadian law, these sites are controversial since the safeguards imposed by Canadian
government to ensure the quality of pharmaceuticals may not be comparable to those imposed by the U.S.
Food and Drug Administration (FDA).9
Type 3: Borderline-Domestic. Other Internet pharmacies oﬀer online medical consultation services together
with prescription-ﬁlling services. Typically, the consumer will ﬁll out a simple online questionnaire about
his diagnosis, medical proﬁle and history, and current medication usage. The questionnaire is reportedly
reviewed by a physician, after which the physician may issue a prescription which will be ﬁlled by the on-
line pharmacy. The cost for the physician review ranges from $35 to $85.10 These sites are controversial.
Critics contend that an online questionnaire is not a suﬃcient substitute for a traditional patient-physician
relationship established through an in person examination.
Type 4: Illicit-Foreign. The most alarming category of Internet pharmacies are those that sell pharmaceu-
ticals without requiring a prescription. All the consumer needs to do is choose the drug he desires and
complete the purchase with a credit card. These types of pharmacies oﬀer FDA-approved medications as
well as medications that have not been approved by the FDA. These sites are the most controversial. Phar-
macies in this category are primarily foreign-based pharmacies that are able to evade the jurisdiction of U.S.
8Allison, Wes, Prescription for Drug Prices: Canada?, St. Petersburg Times, January 7, 2002, at 1A.
9Id.
10GAO Report, supra note 1, at 10-11.
4federal and state laws.11
III. Who Buys From Rogue Internet Pharmacies?
Although rogue Internet pharmacies may be engaging in illegal and unsafe practices, they may nevertheless
be oﬀering a resource that has a net beneﬁt to some individuals in society. In analyzing proposals to regulate
and eliminate rogue Internet pharmacies, it is useful to consider the diﬀerent categories of individuals who
are purchasing or are likely to purchase from these web sites. There are three basic types of customers: those
who wish to procure (1) lifestyle drugs, (2) unapproved drugs, or (3) cheaper drugs.
Lifestyle drugs. Unlike legitimate Internet pharmacies that operate like a traditional pharmacy and oﬀer
a large spectrum of pharmaceutical products, many rogue Internet pharmacies specialize in or limit their
range of products to “lifestyle drugs.” Lifestyle drugs are pharmaceuticals that are taken not to relieve
or cure a medical condition, but are taken instead to improve the quality of life of the person taking it.12
Drugs generally considered as lifestyle drugs include Viagra (for impotence), Propecia (for hair loss), and
Xenical (for obesity). Individuals may turn to rogue Internet pharmacies to purchase lifestyle drugs for
several reasons. Many people may be embarrassed about going to a physician to address the problems for
which the lifestyle drug is prescribed; they can avoid such embarrassment by using an online pharmacy that
will write a prescription based on an online questionnaire or one that does not require a prescription at all.
Some people may mistakenly believe that since these pharmaceuticals are not for the treatment of serious
11Id. at 11.
12One should note that there is dispute about what constitutes a medical condition that needs treatment and what is just
cosmetic, discretionary or even unnecessary.
5medical problems, there is no need to visit a doctor to obtain a prescription. Or, people may turn to rogue
Internet pharmacies because their doctor has turned them down and they want the drug anyway.13
Individuals probably do not turn to these sites to save money. Ordering these medications from rogue Internet
pharmacies often ends up costing more than going to a doctor for an exam and then ﬁlling the prescription
at a traditional pharmacy.14 Although a Consumer Reports survey showed that drugs such as antibiotics,
antihistamines and antidepressants were on average cheaper online, a University of Pennsylvania study found
that lifestyle drugs, such as Propecia and Viagra, are more expensive if purchased online.15 Moreover, the
cost diﬀerential between legitimate online pharmacies and rogue Internet pharmacies seems to be quite large.
For example, a three-month supply of Propecia costs $128 (including $2 shipping) from drugstore.com, a
legitimate Internet pharmacy; $295 (including $75 consultation fee and $18 shipping) from pillstore.com,
an Internet pharmacy that conducts online medical consultations; and, $300 (including $45 shipping) from
pillen2000.com, a foreign-based Internet pharmacy that does not require a prescription.16 Assuming that
the individual does not have health insurance or prescription drug insurance, a physician appointment would
have to cost over $167 to make purchasing Propecia from one of these rogue Internet sites cost-eﬀective. In
addition, comparing costs for a one-year supply of the medication makes the overpricing stark. Assuming,
again, that an individual does not have health or prescription drug insurance, the cost of visiting a physician
during the year for the prescription would have to exceed $668 to make the purchasing Propecia from one
of these rogue Internet sites cost-eﬀective.
Unapproved drugs. Many rogue Internet pharmacies are located in foreign countries. This gives Americans
13Ignelzi, R.J., Online Drug Buyers Gamble with More Than Credit Cards, Washington Wire, August 27, 2001.
14Ignelzi, supra note 13.
15Osher, Chris, State May Force Druggists Online to Take Bitter Pill, The Arkansas Democrat Gazette, May 14, 2000,
at A1.
16Drugstore.com (visited March 24, 2002) <http://drugstore.com>; Pillstore.com (visited March 24, 2002)
<http://pillstore.com; Pillen2000.com (visited March 24,2002) <http://Pillen2000.com>,
6direct access to foreign pharmaceutical markets whereby consumers can purchase medications that are not
available in the United States. The access to drug therapies that have not been approved by the FDA may
beneﬁt individuals who are looking for a cure to a serious medical problem and for whom FDA-approved
drugs have been unsuccessful.
Cheaper drugs. Access to foreign pharmaceutical markets also allows consumers to save money on some
FDA-approved drugs. The United States does not impose price controls pharmaceuticals sold within its bor-
ders. In contrast, most other industrialized countries—including Canada, France, Japan and Germany—do
impose price controls. A 1994 study that compared a “basket” of widely prescribed drugs across countries
found that prices were on average 60% higher in the U.S. compared to other countries.17
The necessity of access to lower-cost pharmaceutical markets is especially relevant for those individuals who
do not have prescription drug insurance. In 1996, about 23% of Americans under age 65 and 27% of Medicare
beneﬁciaries (those over age 65) had no insurance coverage for prescription drugs.18 A recent survey found
that 30% of the uninsured under age 65 said they did not ﬁll a prescription because of cost, compared to
12% of the insured.19 Access to foreign Internet pharmacies may make medications aﬀordable to many of
these individuals who would otherwise go untreated.
Buying medicines from foreign Internet companies can also be cheaper for individuals that do have prescrip-
tion drug insurance coverage. Some consumers have found that buying some drugs from foreign countries is
cheaper than paying what is left after insurance pays its part of the U.S. price.20 Indeed, in a typical PPO
insurance plan, the participant must reach a certain deductible (perhaps $1000 or higher) before prescriptions
are covered. And even once the deductible is covered, most plans require “coinsurance” payments—often up
17Stanton, Jerry. Lessons for the U.S. from Foreign Price Controls on Pharmaceuticals, 16 Conn. J. Int’l L. 149, 165
(2000).
18The Kaiser Family Foundation and the Sonderegger Research Center, Prescription Drug Trends—a Chartbook Up-
date, 3-4 (Nov. 2001).
19Id. at 5.
20Gingerich, Jason W., Web Oﬀers May Ways to Get Drugs, South Bend Tribune, October 30, 2000, at B8.
7to 20% to be paid by the patient.
II. Dangers of Rogue Internet Pharmacies
Online pharmaceutical sales present potential for abuse and misuse at both the consumer and vendor levels.
The dangers to consumers include self-diagnosis and self-medication, lack of suﬃcient medical review, and
substandard products.
Self-diagnosis and self-medication. Since some Internet pharmacies allow customers to purchase pharmaceu-
ticals without a prescription, this allows customers to self-diagnose and self-medicate. Self-diagnosis and
self-medication are dangerous because consumers lack safeguards that are present in the traditional distri-
bution channel for pharmaceuticals which informs patients on proper dosage, possible side eﬀects, and drug
interactions. Some conditions allayed by drugs may have underlying causes that are not obvious and which
can only be diagnosed by a thorough medical examination. For example, a person may purchase Viagra
to treat impotence, but the cause of the impotence could be a pituitary tumor, diagnosed only through a
physical exam and laboratory tests.21 In the worst case scenario, self-medication can result in death. For
instance, in March 1999, a 52-year old man with a family history of heart disease died of a heart attack
after buying Viagra from on online site that required no prescription.22 In November 1999, a man in his
20’s who was suﬀering from chronic depression died of a accidental overdose from ingesting controlled sub-
21Prescription for Trouble, Consumer Reports, February 2001, at 19.
22Ignelzi, supra note 13.
8stances obtained from a overseas pharmacy without a prescription.23 And although a physician-obtained
prescription does not guarantee that there is a proper diagnosis or proper use of the medication, the risk
of negative outcomes such as harmful drug interactions, contra-indications, allergic reactions or improper
dosing is greatly lower.
Flawed Review Process. The companies that require customers to ﬁll out a questionnaire to obtain a pre-
scription may seem safer than those that require no prescription at all, however, it is possible that a licensed
physician may never review the information. There are numerous stories about people who have been able to
obtain drugs online posing as animals, dead people, young children, or as patients with clear contra-indicated
conditions. One news reporter, investigating the dangers of online prescribing, procured Viagra for a cat
from one website. He truthfully ﬁlled out the questionnaire and stated that the patient stood 6 inches tall,
weighed 15 pounds and was neutered. The reporter was also able to procure Viagra from another website for
an imaginary person who revealed clear contra-indications on the questionnaire—heart trouble and current
use of nitrate medicines.24 Clearly in both cases, there was no medical review of the questionnaires.
Even if the questionnaire is actually reviewed, there is often no way to assure that this review process
is suﬃcient. Many rogue Internet pharmacies do not disclose associated physicians or pharmacists, and
thus there is no way to check the credentials of the healthcare professionals or conﬁrm whether healthcare
professionals are used at all. Individuals not licensed to prescribe or sell prescription drugs can easily design
a website that appear to represent legitimate a pharmacy.25 Where a licensed physician does review the
questionnaire, there is more room for error than if the physician actual sees the patient. Moreover, there
23Continuing Concerns over Imported Pharmaceuticals: Hearings Before the Subcommittee on Oversight and Investigations
of the House Committee on Energy and Commerce, 107th Cong. at 25 (2001) [Hereinafter Hearings 2001] (testimony of Edwin
and Helen Rode).
24Yeoman, Barry, Drugs Online the New Danger, Ladies Home Journal, May 1, 2001.
25Enforcing the Law on Internet Pharmaceutical Sales: Where are the Feds?: Hearing Before the Subcommittee on Oversight
and Investigations of the House Comittee on Commerce, 106th Cong. at 15 [Hereinafter Hearings 2000] (prepared statement
of William K. Hubbard, Senior Associate Commissioner of the FDA).
9is the possibility that the terms used in the questionnaire may be beyond the technical comprehension of
the consumer, and since many forms are already ﬁlled out with the “correct” answers necessary to obtain a
certain pharmaceutical, contra-indicated conditions may be missed. 26
Additionally, there is no mechanism to ensure that consumers are answering questions truthfully; most rogue
Internet pharmacies make no eﬀort to conﬁrm the accuracy of the questionnaires. For example, when one
woman ordered the diet drug Xenical, the order was originally denied because her weight entered was too
low. No problem: she simply increased her weight in the questionnaire, and the order was approved.27 Such
deception would not have been possible in a traditional physician-patient relationship.
Substandard Products. One congressman has likened buying drugs online to the “healthcare equivalent of
trick-or-treating in a bad neighborhood.”28 A U.S. Customs oﬃcial likened it to “playing Russian roulette
with your life.”29 Even if the individual has a diagnosed medical problem and has obtained a prescription
from a physician, there is still the risk that the products procured will be substandard. This is especially a
problem encountered by purchasing pharmaceuticals from a foreign-based pharmacy.
In the United States, the Food, Drug and Cosmetic Act (FDCA) prohibits the manufacture and distribution
of misbranded and adulterated drugs and requires drugs to be handled in ways that prevent them from being
contaminated. Foreign countries may not have or enforce similar regulations and the risk of substandard
goods is high. Some estimate that the percentage of counterfeit and substandard imported drugs could be
as high as 25% of the imports.30
Although a foreign website may advertise the sale of FDA-approved, U.S.-made medications, such represen-
26Yeoman, supra note 24.
27Id.
28Hearings 2000, supra note 25, at 2 (statement of Congressman Fred Upton).
29Ignelzi, supra note 13.
30Hearings 2001, supra note 23, at 20 (prepared statement of Congressman Bobby Rush).
10tations may be false. Even if the customer receives a product that looks identical to one purchased in the
United States, the product may be counterfeit. The production of counterfeit mediations is pervasive outside
the United States. According to one pharmaceutical industry expert, “counterfeiters are able to produce
labels that are virtually indistinguishable from the true labels.”31 These counterfeit medications may contain
expired ingredients, adulterated ingredients, or dangerous sub-potent or super-potent ingredients.32 And,
there is no guarantee that these products contain any active ingredients at all or that they are manufactured
and packaged under sanitary conditions. One Internet pharmacy based in a vermin-infested warehouse in
Bangkok had kids stuﬃng bags with “Viagra” pills made from Vodka paste and which were strewn all over
the ﬂoor.33 Drugs ordered from Internet pharmacies in countries with strict regulations like Canada also do
not assure drugs meet the FDA standards for quality. Canada could become an entry point for substandard
foreign drugs seeking access to the U.S. market and the FDA cannot assure that Canadian quality controls
are suﬃcient.34
III. Current Regulatory Scheme for Domestic Internet Pharmacies.
With all the dangers posed by prescribing and dispensing practices of rogue Internet pharmacies, something
must be done to curtail these activities. There are four potential sources of action that could protect con-
sumers from the unethical and unsafe practices of Internet pharmacies located within the United States:
private actions, industry self-regulation, state action and federal action.
Private Actions. If consumers could ﬁle malpractice or other private actions against Internet pharmacies, this
could deter Internet pharmacies from engaging in dangerous prescribing and dispensing practices. Unfortu-
31Hearings 2001, supra note 23, at 158 (statement of John D. Glover, Vice President of Corporate Security, Bristol-Meyers
Squibb).
32Id.
33Ignelzi, supra note 13.
34Allison, supra note 8.
11nately, due to the use of “clickwrap” waivers, consumers who are harmed by the medications they purchase
may not have legal recourse against rogue Internet pharmacies. Clickwrap provisions are a system used in
e-commerce that prevent a user from carrying out an action on the website until they have agreed to the
terms and conditions of use. The terms and conditions of use generally pop up in a new window and allow
a user to signal assent with an on-screen click. If the user does not agree to the terms and conditions, the
website is designed so that the visitor cannot proceed any further.
Many rogue Internet pharmacies use clickwrap waivers to disclaim liability. For example, one website re-
quires a consumer to waive “any and all liability associated with or arising from the physician consultation or
from the medical, physical, behavioral or other eﬀects of any medication that may be ordered, prescribed or
purchased as a result of the physician consultation.”35 The 1999 GAO study of Internet pharmacies revealed
that only rogue Internet pharmacies use liability waivers. The GAO found that of 111 identiﬁed pharmacies
that require a prescription, 0 used such waivers; of 54 identiﬁed pharmacies that issue prescriptions after
reviewing questionnaires, 45 (or 83%) used such waivers; of 25 identiﬁed pharmacies that do not require a
prescriptions, 18 (or 72%) used such waivers.36 Internet pharmacies that engage in high-risk prescribing and
dispensing practices are counting on the clickwrap waivers to protect them from consumer liability.
Unfortunately, courts are likely to enforce clickwrap waivers against individuals who purchase from rogue
Internet pharmacies. Some consumer rights proponents have argued that clickwrap agreements should not be
upheld, since consumers do not read such boilerplate.37 Nevertheless, with respect the clickwrap agreements
as they apply to e-commerce in general, the trend in case law has been to enforce such agreements as long
as the customer’s assent is suﬃciently aﬃrmative and as long as the contract is not unconscionable.38 If
35E-scripts-md.com, Patient Responsibility Statement and Statement of Informed Consent (viewed March 2, 2002) <http://
www.e-scripts-md.com/patient responsibility.asp>.
36GAO Report, supra note 1, at 10.
37Vartanian, Thomas, Guest speaker, Exploding Internet Class, Harvard Law School (Feb. 20, 2000).
38Gray, Megan and Brian Ross, Contracts Drafting Stronger Clickwrap Agreements, The Internet Newsletter 6.6, Sept.
2001, at 1 – 6.
12the customer aﬃrmatively clicks on an “I Agree” button, the customer is typically deemed to manifest the
necessary asset.39 There has only been one case on clickwrap agreements in the context of Internet phar-
macies. Recently, the Supreme Court of Kansas held that a clickwrap agreement that released an Internet
pharmacy from all consumer liability was not unconscionable under state law.40 According to the Court,
there must be some element of deceptive bargaining.41 Since nothing was misrepresented by the website
and all drugs furnished were authentic, the agreement was valid.42 One commentator has noted that courts
have a tendency to override waivers in healthcare settings, and as a result, has predicted that clickwrap
agreements are unlikely to be upheld in the context of Internet pharmacies.43 Whether other courts will
follow the reasoning of the Supreme Court of Kansas remains to be seen. Given the trend toward enforcing
clickwrap agreements in e-commerce, other courts may follow the lead of the Kansas.
Industry Regulation. Industry self-regulation is another potential form non-governmental regulate Internet
pharmacies. The National Association of Boards of Pharmacy (NABP) has made an attempt an attempt at
industry self-regulation.44 In 1999, NABP developed a program called Veriﬁed Internet Pharmacy Practice
Sites (VIPPS) to help customers identify if an Internet pharmacy is legal and is maintaining certain quality
standards. To qualify for the VIPPS seal, which an online pharmacy can post on its web site, an online
pharmacy is required to satisfy 17 Internet pharmacy criteria. These criteria include complying with the
licensing requirement of each state in which the pharmacy dispenses medications, passing an on-site visit
from the VIPPS inspection team at the pharmacy’s headquarters, meeting certain levels of security and
integrity for its medication, information and services, and oﬀering immediate access to a pharmacist so that
39Id.
40Kansas v. Conﬁmed.com, 38 P.3d 707, 712 (Kansas Sup. Ct. 2002).
41Id. at 713.
42Id. at 714.
43Chuang, Chester, Is there a Doctor in the House? Using Failure to Warn Liability to enhance the Safety of Online
Prescribing, 75 N.Y.U. L. Rev. 1452, 1488 n.18 (2000).
44The NABP was established in 1904 to assist state licensing boards in developing, implementing, and enforcing uniform
standards to protect the Public Health. Pharmacy boards from ﬁfty states, the District of Columbia, three U.S. territories,
nine Canadian provinces, and four Australian states make up the association membership.
13customers can report any medication problems. In addition, they must provide a link on their web site to the
NABP so that consumers can report any problems they might encounter with the web site.45 To date, only
fourteen Internet pharmacies have been awarded VIPPS certiﬁcation.46 While such certiﬁcation may help
customers who are trying to locate a legitimate Internet pharmacy, because it is not a mandatory system,
it does nothing to reduce the supply of Internet pharmacies that cater to customers who wish to obtain a
pharmaceutical without a prescription obtained from a traditional physician-patient relationship.
State Regulation of Domestic Internet Pharmacies. Since private actions and industry self-regulation have
not been suﬃcient to regulate Internet pharmacies, government regulation is necessary. Most enforcement
actions against rogue Internet pharmacies and associated physicians located within the United States have
come from state action. Internet case law indicates that the proper jurisdiction for legal action resides in the
state where the purchaser lives, not the location of the Internet business.47 Thus, state attorney generals
can ﬁle lawsuits against online pharmacies outside the state as well as those in their jurisdiction.
State attorneys general have based actions on a variety of legal theories, seeking injunctions and civil penal-
ties. Some states have ﬁled lawsuits against Internet pharmacies dispensing pharmaceuticals to its residents
without being licensed by its state board of pharmacy. Thirty-nine states require pharmacies to be licensed
in the state in which they are based, as well as in each state where the patients reside.48 Some states have
ﬁled lawsuits against Internet pharmacies for violating state consumer protection laws by giving the false
impression that completing an online questionnaire is comparable to a doctor’s examination.49 Other states
have charged individual physicians who prescribe medications based on questionnaires rather than conduct-
ing physical evaluations with violating state statutes prohibiting “unprofessional conduct” or violating state
45National Association of Boards of Pharmacy , VIPPs Criteria (last modiﬁed Nov. 29, 1999)
<http://www.nabp.net/vipps/consumer/criteria.asp>.
46National Association of Boards of Pharmacy , Veriﬁed Internet Pharmacies List (viewed April 1, 2002)
<http://www.nabp.net/vipps>.
47Zippo Mfg. Co. v. Zippo Dot Com, 952 F. Supp. 1119 (D. Pa. 1997) (holding that that the defendant’s conduct of
electronic commerce with Pennsylvania residents constituted “purposeful availment” of doing business in Pennsylvania).
48Kearney, Kerry and Celia Santander, Telemedicine: Evolving into Cyberspace, Health Lawyer, April 2001.
49Goetz, John and Donald Lund, What the Law Allows, Pharmaceutical Executive, August 1, 2000, at 76.
14medical practice laws.50 The American Medical Association (AMA) has taken the position that the issuance
of a prescription based solely on an online questionnaire for the patient does not meet the appropriate stan-
dard of care and is not a valid prescription.51 The State Federal of Medical Boards (FSMB) has taken the
position that prescribing of medication by physicians based solely on an electronic medical questionnaire is
outside the bounds of professional conduct.52 Nevertheless, whether an online questionnaire can result in a
valid prescription may vary across states, since the applicable standard of care is determined by each states’
medical practice laws.
Despite state eﬀorts to prosecute rogue Internet pharmacies, these actions, without new federal and state
legislation, will not be suﬃcient to curb illegal activities by domestic Internet pharmacies. Many state reg-
ulators and agencies lack the resources and expertise necessary to investigate and prosecute violations.53
State regulators have encountered diﬃculty in identifying and locating the physicians, pharmacists and prin-
cipals involved.54 In absence of direct physical injury to customers, state oﬃcials may not see these cases
as priorities given limited resources.55 Even when a state successfully prosecutes an out-of-state Internet
pharmacy and its associated physicians and pharmacists and stops them from prescribing and dispensing
drugs to residents of that state, the court action applies only in that state. And, if a state brings an action
against an Internet pharmacy located within its borders, the pharmacy could simply re-open operations in
another state. This jurisdictional limitation also prevents state medical and pharmacy boards from eﬀec-
tively curbing rogue Internet pharmacies. State medical and pharmacy boards can also impose sanctions
upon a doctor or pharmacist who is engaging in unethical or illegal activities. However, if a board comes
50Id.
51American Medical Association, Internet Prescribing, (visited April 12, 2002) < http://www.ama-
assn.org/meetings/public/annual99/reports/onsite/bot/rtf/bot35.rtf>
52Federation of State Medical Boards, The Report on the Special Committee on Professional Conduct and Ethics, § IV,
Internet Prescribing (visited April 16, 2002) <http://www.fsmb.org>.
53Cleland, Richard L., Cross-Border Telemedicine: an Uncertain Future, Saint Louis University Law Journal 149, 154
(Winter 2002).
54Hearings 2000, supra note 25, at 11 (statement of William Hubbard).
55Cleland, Richard L., Cross-Border Telemedicine: an Uncertain Future, Saint Louis University Law Journal 149, 154
(Winter 2002).
15across a doctor or pharmacist licensed in another state and dispensing prescription drugs to residents in the
board’s state, the board has no jurisdiction to impose sanctions. The board is limited to sending warnings
or lodging complaints with the counterparts on the medical and pharmaceutical boards where the online
pharmacy, physician or pharmacist is located.
Within the last couple years, some states have enacted legislation aimed speciﬁcally at the conduct of phar-
macies conducting business over the Internet. These statutes adopt strict disclosure requirements, make
VIPP certiﬁcation a mandatory requirement, clarify the deﬁnition of a valid prescription, clarify the need
for out-of-state pharmacies to be licensed where the customer resides, and/or impose large civil penalties or
criminal sanctions for failing to comply with the statute. For example:
•
An Arkansas statute requires Internet pharmacies that dispense pharmaceuticals to Arkansas residents to disclose information regarding the principals, physicians and pharmacists associated with the site, and to either obtain licensing from the state board of pharmacy or obtain VIPP certiﬁcation.56 The licensing fee is $300, renewable biennially for $150.57 Violation of the act is an unconscionable trade practice and the state can impose civil penalties of up to $10,000 per violation.58
•
Nevada has enacted legislation making it a felony for Internet pharmacies that are not licensed by the state board of pharmacy to dispense prescription drugs to those whom it has reason to believe are Nevada residents.59 The cost to apply for a license in Nevada is $600, renewable biannually for $500.60 It is also a felony for practitioners to give a prescription to patients whom they have not examined during the preceding six months.61 Violators could be imprisoned for up to 10 years and ﬁned up to $10,000.62
•
New York enacted legislation requiring the registration of nonresident pharmacies that mail or deliver prescription drugs to New York patients. The registration fee is $345, renewable triennially for $260.63 In addition, a consumer protection act was introduced in the New York legislature that would require certain disclosures on an Internet website, disallow limitations of liability and create a class A misdemeanor for violations of the bill.64
The problem with these legislative actions is that they make it expensive for a legitimate online pharmacy
16to operate if it has to undergo strict licensing procedures and pay licensing fees for each state. Since each
state has diﬀerent requirements as to the frequency of licensing fees, compliance may be diﬃcult for Internet
pharmacies. And, since each state has diﬀerent requirements as to what information the Internet pharmacy
must reveal on its website, this would eﬀectively require an Internet pharmacy that wishes to serve the U.S.
market to comply with the strictest state regulations. All these burdens placed upon Internet pharmacies
by the new legislative actions leads to the possibility that these statutes may violate the dormant Commerce
Clause.
The dormant Commerce Clause of the United States Constitution poses a signiﬁcant question about the
validity of state attempts to regulate Internet pharmacies through new legislation. The Commerce Clause
provides: “the Congress shall have Power...To regulate Commerce...among the several States....”65 The
negative or dormant implication of the Commerce Clause prohibits state regulation that unduly burdens
interstate commerce.66
The leading case on the application of the dormant Commerce Clause to the Internet is American Libraries Association v. Pataki.67
The case involved a New York statute that prohibited intentional use of the Internet to engage in porno-
graphic communications deemed to be “harmful to minors.” The United States District Court for the
Southern District of New York held that the New York statute was an unconstitutional intrusion into inter-
state commerce. It is diﬃcult for Internet users to control access to their websites, newsgroup postings, and
other communications, and fear of liability in New York might chill activities by Internet users operating
legally in other states.68 Since other states regulate pornographic communications diﬀerently, “a single actor
might be subject to haphazard, uncoordinated, and even outright inconsistent regulation by states that the
65U.S. Const. art. I, § 8, cl. 3.
66Goldsmith, Jack L. and Alan O. Sykes, The Internet and the Dormant Commerce Clause, 110 Yale L.J. 785, 786 (2001).
67American Library Association v. Pataki, 969 F. Supp. 160 (D. N.Y. 1997).
68Id. at 177.
17actor never intended to reach of possibly was unaware were being accessed.”69 In addition, the court stated,
“the Internet is one of those areas of commerce that must be marked oﬀ as a national preserve to protect
users from inconsistent legislation that...could paralyze development of the Internet altogether.”70
Taken to an extreme, the Pataki decision would invalidate every state attempt to regulate the Internet,
including attempts to regulate Interstate pharmacies. Not all Commerce Clause scholars, however, would
agree with such a broad interpretation of the dormant Commerce Clause. According to Jack Goldsmith and
Alan Sykes, professors of law and Chicago Law School, the fact that a state Internet regulation imposes costs
on out-of-state actors cannot by itself be the basis for illegality under the dormant Commerce Clause:
A more plausible interpretation of the inconsistent-regulations concern is that non-uniform
state regulations might impose compliance costs that are so severe that they counsel against
permitting the states to regulate a particular subject matter. At the limit, actors may be-
come subject to diﬀerent regulations to such an extent that compliance becomes eﬀectively
impossible if they are to engage in interstate commerce. Similarly, ﬁrms may become sub-
ject to regulatory requirements in one jurisdiction that accomplish no more than diﬀerent
regulatory requirements imposed by another jurisdiction, with the result that regulatory
compliance costs increase signiﬁcantly for no good reason. The same regulatory beneﬁts
could be obtained at lower cost if the states simply adopted the same policies or restated
their policies in terms that allowed regulated entities to comply by choosing among the
various equally eﬀective compliance options. 71
Thus, in applying the dormant Commerce Clause, the courts must apply a balancing test, and where the
statute eﬀectuates a legitimate local public interest, it should be upheld unless the burden imposed on
interstate commerce is excessive relative to the local beneﬁts.72
The newly enacted state laws which attempt to regulate Internet pharmacies may or may not violate the
dormant Commerce Clause, depending on whether they fail the balancing test. According to Goldsmith
and Sykes, regulations that involve the out-of-state provider of real-space goods are less likely to violate
the dormant Commerce Clause than those that involve the transmission of digital goods over the Internet,
69Id. at 168.
70Id. at 181.
72Id. at 804.
18since the provider or real-space goods can more easily determine where the goods are going and research
and comply with local regulations.73 Nevertheless, this fact is not conclusive of whether the new state laws
regulating Internet pharmacies would violate the dormant Commerce Clause. If states have similar licensing
requirements for health care professionals, it does seem duplicative to require them to register and pay
corresponding licensing fees in each state to which they dispense medications. Indeed, the same regulatory
beneﬁts could be obtained at a much lower cost if the states simply adopted the same policies or restated
their policies in terms that allowed the Internet pharmacies to comply by choosing among the various equally
eﬀective compliance options.
Federal Regulation of Domestic Internet Pharmacies. The Food, Drug and Cosmetic Act (FDCA) generally
prohibits the manufacture and distribution of misbranded and adulterated drugs, and requires drugs to
be labeled accurately and handled in ways that prevent them from becoming contaminated or misused.
Products that qualify as prescription drugs under the FDCA can only be dispensed with a valid prescription
from a licensed doctor. If a pharmacy sells drugs without a valid prescription, the products are considered
“misbranded” and the pharmacy is in violation of the law.74 Violators can be imprisoned for up to one year
and ﬁned up to $1,000. Repeat oﬀenders can be imprisoned for up to three years and ﬁned up to $10,000.75
The FDCA applies to all pharmacies, traditional and those online. Clearly, Internet pharmacies that do not
require a prescription would be selling “misbranded” drugs in violation of the FDCA. Internet pharmacies
which request some medical information and pass it on to a web doctor, may or may not violate the FDCA,
depending on whether the transaction constitutes a valid prescription under state law. As discussed above,
73Id. at 824.
74FDCA §§ 301, 503, 21 U.S.C. §§ 331, 353 (2002) (FDCA § 301(a) cites as a prohibited act the introduction into interstate
commerce of any drug that is “misbranded.” According to FDCA § 503(b)(1)(B), a drug “shall be dispensed only...upon a
written prescription of a practitioner licensed by law to administer such drug” or upon an equivalent verbal prescription which
is promptly reduced to writing. If a drug is dispensed contrary to this provision, the drug shall be deemed misbranded.)
75FDCA § 303(a), 21 U.S.C. § 333(a) (2002).
19the AMA and the FSMB agree that a prescription issued solely based on an online questionnaire is not a
valid prescription. But, despite the views of these associations, it is state law that governs. If the state does
not attest that the prescription being written is invalid, the FDA has diﬃculty bringing a successful case.76
The lack of consistent state laws on what constitutes a “valid prescription” is not the only impediment
to successful FDA actions. The FDA lacks suﬃcient resources to deal with the problem of rogue Internet
pharmacies. The FDA has expressed the same diﬃculty as state actors: investigations are diﬃcult and
costly because so few rogue Internet sites list addresses or identifying information.77 These impediments
may explain why, as of June 2001, the FDA actions have only resulted in ﬁve criminal convictions and no
reported successful civil actions involving the sale prescription drugs without a “valid prescription.”78
Another possible source of federal action is through the Federal Trade Commission Act (FTCA) which
implicates activities which may be “misleading” or “unfair,” including Internet pharmacies that make false
or misleading claims about the products of services they provide. For example, in FTC v. Rennert, the
FTC claimed that the defendant’s Internet pharmacy falsely represented that the customers were served by
a clinic with physicians and an on-site pharmacy.79 In reality, the Internet pharmacy employed only one out-
of-state physician to review the medical questionnaires. Other possible representations, if false or misleading,
may violate the FTCA include a representation that (1) the product is safe, (2) that an online consultation
is equivalent to a physician examination, or (3) that a pharmacy is licensed to dispensed medications in
the customer’s state. But, despite these possibilities for further FTC action, FTC oﬃcials have recently
announced that they back away from such actions and leave the regulation of Internet pharmacies to state
laws and the state attorneys general.80
76Id. at 12.
77Hearings 2000, supra note 25, at 15-19.
78Hearings 2001, supra note 23, at 54.
79Federal Trade Commission, Online Pharmacies Settle FTC Charges, (viewed February 4, 2002)
<http://www.ftc.gov/opa/2000/07/iog.htm>.
80Agency Actions, Washington Internet Daily, Vol.3., No. 55, March 21, 2002.
20IV. Current Regulatory Scheme for of Foreign Internet Pharmacies.
Although regulating and prosecuting domestic Internet pharmacies as operators has proved diﬃcult under
existing law, controlling the activities of foreign-based Internet pharmacies has proved nearly impossible due
to the lack of U.S. jurisdiction.
Food, Drug and Cosmetic Act. The federal government has the constitutional authority to regulate foreign
Internet pharmacies as an aspect of interstate or international commerce. The main source of federal au-
thority to combat foreign Internet pharmacies is the FDCA. With respect to the practices of foreign Internet
pharmacies that sell to U.S. customers, The FDCA prohibits the “introduction or delivery for introduction
into interstate commerce” of:
•
“misbranded drugs,” including drugs issued without a valid U.S. prescription,81
•
“adulterated drugs,” including drugs that are packed or held in unsanitary conditions, drugs that are of substandard quality or purity, and drugs that are not manufactured according to the FDCA’s good manufacturing practice,82
•
“new or unapproved drugs,” including foreign drugs of which there are no approved U.S. equivalents and foreign-made versions of U.S. approved drugs,83 and
•
“reimported drugs,” meaning drugs that have that are approved and manufactured in the U.S. and were previously sold to distributors outside the U.S, unless the drug is re-imported by the manufacturer of such drug.84
21Under these provisions, it would seem that all pharmaceuticals that are imported into the United States are
illegal and all foreign Internet pharmacies that send drugs into the U.S. are breaking U.S. law.
Cyber Letters & International Cooperation. Although all foreign Internet pharmacies that sell to U.S. con-
sumers violate these laws, it is eﬀectively impossible for the FDA to pursue these pharmacies. They are
beyond the jurisdiction of the United States. Even if the FDA had jurisdiction, it would have diﬃculty
tracking down violators, since the websites do not reveal the operators or the location of the business. In an
attempt to deter foreign Internet pharmacies from selling to U.S. citizens, the FDA has resorted to “cyber
letters” and international cooperation.
In February 1999, the FDA began sending e-mails to foreign-based pharmacies, warning them that their
prescription drug sales to U.S. citizens are illegal. The letters advise the recipients that it is illegal to sell
prescription drugs to U.S. citizens without a valid prescription, clarify the FDA’s policy on personal use
importation, and warn site operators that packages shipped will automatically be detained at the U.S. bor-
der. If the location of the operators can be identiﬁed, copies of the warning letters are sent to the FDA’s
counterpart in each foreign country, requesting an investigation.85 These eﬀorts have produced some results.
About 25% of the recipients comply with the request to discontinue illegal dispensing practices.86 Of course,
that means 75% are ignoring the FDA letters, so while the program may have some eﬀect on deterrent eﬀect,
it has hardly been a success. Indeed, even though the FDA sends copies if the warning letters to regulator
oﬃcials in the countries where the sites are based, the foreign countries do not seem to be responding to
the FDA’s concerns. FDA oﬃcials recently stated they knew of no instance of a cyber letter prompting a
foreign government to shut down a ﬁrm or resulting in the imposition of criminal or civil penalties by a
85Hearings 2000, supra note 25, at 19 (prepared statement of William K. Hubbard).
8625% of Cyber Letters Spur Compliance, But Few Cases Concern Drug Counterfeiting, Warning Letter Bulletin,
Novermber 5, 2001.
22foreign country.87
Obtaining the cooperation of some foreign governments may be possible if U.S. agencies assist foreign agen-
cies in gathering evidence against rogue Internet pharmacies. For example, in 1999, U.S. Customs oﬃcials
gathered evidence against a Thai Internet pharmacy that exported pharmaceuticals to the U.S. and they
worked directly with Thai customs in identifying the operators and pinpointing the location of the opera-
tion. In March 2000, this joint operation by U.S. and Thai customs agents led to the arrest of 21 people.88
But, even if U.S. regulators work with foreign regulators to obtain information against Internet pharmacies,
diﬀerences in foreign laws may make such eﬀorts futile. For example, when the New Zealand Ministry of
Health tried to enjoin a pharmacist from exporting drugs to U.S. citizens without a prescription, a New
Zealand court held that a loophole in the New Zealand federal law lets pharmacists dispense drugs without
a prescription to customers outside the country.89
Overall, any U.S. attempt to curtail the supply of foreign Internet pharmacies seems futile. Even if some
nations have the legislative authority to enjoin foreign sales of pharmaceuticals by businesses in their country,
many may not. In the current business climate, many countries, especially developing countries, may be
more likely to encourage, rather than discourage, pharmaceutical exports.90 It may be impossible for the
U.S. to obtain the cooperation of countries that permit the sale of most drugs without prescriptions. And,
even if the U.S. is able to obtain the cooperation of some countries to shut certain websites down, the eﬀort
will only put a small dent in the supply of foreign Internet pharmacies, since websites will open in countries
that do not cooperate with the U.S. government.
Seizures. Since the federal government cannot eﬀectively control the distribution of foreign-source phar-
87Id.
88Goldman, Charles, Recent Enforcement and Regulatory Activity Relating to the Internet Pharmaceutical Industry (visited
March 24, 2002) <http://ebglaw.com>.
89Pharmacy Law: New Zealand’s Legal Loophole, 133 Canadian Pharmaceutical Journal 16 (2000).
90Otrompke, John. Internet Likely to Open Brave New World in Global Pharmaceuticals Trade, Medicine & Health,
October 9, 2000, at S1.
23maceuticals outside its borders, one alternative is to curtail distribution of these goods once they enter
the country. Citizens who order misbranded, adulterated, unapproved or reimported pharmaceuticals from
rogue Internet pharmacies are also breaking the law. The FDCA provides a criminal enforcement option that
would allow a violator to be imprisoned for up to a year or ﬁned up to $1,000.91 The FDCA also permits
the federal government to refuse admission to illegal pharmaceutical imports.92 Although the FDA has the
statutory authority to impose criminal penalties on consumers, the FDA has chosen to enforce the FDCA
against consumers primarily through seizures. The FDA also has decided not to strictly apply the law against
consumers who import pharmaceuticals. In 1954, the FDA developed a “compassionate use” or “personal
use policy” regarding the importation of prescription drugs. As originally adopted, this policy permitted
U.S. residents to obtain unapproved, foreign-made pharmaceuticals while traveling in a foreign country. In
1988, the policy was amended to allow seriously ill patients to import potentially eﬀective treatments that
were not approved for use in the United States. The current oﬃcial personal use policy of the FDA allows
entry of an unapproved prescription drug if:
•
the product is for personal use (not to exceed a 90-day supply);
•
the product is for the treatment of a serious condition for which eﬀective treatment is unavailable in the U.S.;
•
91FDCA §303(a), 21 U.S.C. §333(a) (2002).
92FDCA §801(a), 21 U.S.C. §381(a) (2002).
24the product does not pose an unreasonable health risk; and
•
the individual provides documentation that a doctor licensed in the U.S. is overseeing the treatment with the product or that the product is for the continuation of a treatment begun in a foreign country.93
Since permissible imports must be for a serious condition for which eﬀective treatment is unavailable in the
U.S., this policy has never allowed the importation of foreign versions of U.S.-approved drugs nor reimpor-
tations of U.S-approved drugs.94 Unfortunately, this policy has proven diﬃcult to implement.
The seizure of illegal imports requires many levels of coordination between Customs and the FDA. Customs
oﬃcials identify packages that may violate the FDCA. Customs then refers these packages to the FDA
to determine if they are indeed violations and should be detained. If they are detained, the Drug Import
Fairness Act requires the FDA to give the importer due process. The FDA must send notice to the addressee
explaining the violation and must permit an opportunity for the person to respond. If the addressee does
not respond or provides an unsatisfactory response to legitimize the shipment under the FDA’s personal
use policy for importations, the FDA returns the parcel to Customs and Customs returns the parcel to the
sender.95
In theory, the FDA’s personal use and seizure program seems like a good policy since it allows people
with serious illness to obtain alternative treatments and since it protects people from potentially dangerous
drugs where a safe treatment exists in the U.S. Unfortunately, due to limited resources, Customs and the
FDA are unable to review all packages that enter the U.S. mail system from foreign sources. There are 14
international mail processing facilities, and Customs has diﬃculty detecting illegal pharmaceutical imports
94Hearings 2001, supra note 23, at 48 (prepared statement of William Hubbard).
95Id.
25among the tens of millions of parcels passing through the mail facilities each year.96 Due to the large volume
of incoming packages, Customs is only able to x-ray 10 – 15% of the packages based upon which ones appear
to be high risk and they forward the rest to addressees without inspection.97 With respect to the packages
that Customs detains, the FDA has diﬃculty reviewing all the packages since there are only 150 inspectors
nationwide to analyze the imports.98 For example, at one Customs facility that receives several thousand
pharmaceutical shipments each week, the FDA only staﬀs three employees who are able to review about
30 packages a day.99 Furthermore, it is impossible for the FDA to conduct forensic testing, or authenticity
testing, to ensure the quality of personal imports since such tests costs $6,000 - $15,000 per box of drugs.100
In short, despite the stringent requirements to qualify for the Personal Use Policy for importation, many
packages that violate the policy are released to customers, even after a thorough inspection by Customs.
According to Elizabeth Durant, an Executive Director of U.S. Customs, “[f]or the most part, if the parcel
doesn’t contain a [controlled] substance, it is released back to the Postal Service for delivery.”101 Federal
oﬃcials estimate that about 200,000 pharmaceutical parcels per month are coming into the U.S. without
review.102
V. Policy & Proposed Regulations.
Clearly the current regulatory scheme is insuﬃcient to eﬀectively curtail the practices of rogue Internet
pharmacies. More legislation, regulation and funding is needed if one believes that these businesses pose an
unacceptable risk to the health of Americans.
96Id. at 41 (testimony of Elizabeth Durant, Executive Director of Trade Programs at U.S. Customs).
97Id. at 72 (testimony of Elizabeth Durant, Executive Director of Trade Programs at U.S. Customs).
98Id. at 63 (testimony of William Hubbard).
99Id. at 97 (letter from Congressman John Dingell to Bernard Schwetz, Acting Principal Deputy Commissioner, Food and
Drug Administration).
100Id. at 70 (testimony of William Hubbard).
101Id. at 64 (testimony of Elizabeth Durant).
102Id. at 9 (prepared statement of Congressman John D. Dingell).
26Direct Internet Regulation. The most direct approach to eﬀectively combat illegal Internet pharmacies would
be to regulate the Internet directly and prevent these webpages from reaching consumers. The federal or
state government could simply ﬁlter Internet content itself or require the ﬁltration of Internet content by
third parties, such as Internet service providers. This could be done by “blacklisting” or “whitelisting”
Internet pharmacy sites. Under blacklisting, access is given to all sites except those listed on the “black”
list. Conversely, under whitelisting, access is blocked to all sites except those on the “white” list. The
white list could be generated either by humans or by content-examination software. Alternatively, the
Internet Corporation for Assigned Names and Numbers (ICANN), a privatized regulatory body which is
under contract with the federal government to make policy assigning domain names and web address, could
intervene. ICANN could implement a policy disallowing domain names to e-pharmacies that do not meet
certain standards. Unfortunately, any one of the above options is likely to be challenged as unconstitutional–
a violation of the freedom of speech or as an illegal restraint of trade. Additionally, such regulations are
likely to be politically unfeasible in the near future, given the widespread sentiment that the growth of the
Internet should not be impeded in any way.
Proposed Federal Legislation. Several bills have recently been proposed in Congress that directly address
the problem of Internet pharmacies:
•
The Internet Prescription Drug Sales Act was submitted by the Clinton administration to Congress in May 2000. It would require pharmacy sites to certify with the Health and Human Services (HHS) 30 days before launching a web site that: it is licensed to practice pharmacy in each state in which it operates and to which it delivers prescription drugs, it complies with all federal and state pharmacy laws, and it posts certain mandatory information on its home page. HHS would be able to assess civil penalties up to $500,000 for Internet pharmacies that violate the licensing requirements. In addition, the proposal would allocate $10 million to the FDA to combat illegal Internet pharmacies, and give state attorneys general the ability to obtain nationwide injunctions.103
•
27The Internet Pharmacy Consumer Protection Act was introduced in October 2000. It would require the disclosure of information such as street address, phone number and states in which the Internet pharmacy is licensed to sell products. The bills would also give state attorneys general the ability to obtain nationwide injunctions and would give the FDA the ability to stop illegal operators from collecting payments from U.S. customers by bringing a civil action to enjoin the transfer funds traceable to illegal transactions.104
The adoption legislation similar to that of the Internet Prescription Sales Act will be more eﬀective against
curtailing the activities of rogue Internet pharmacies located domestically. As discussed above, the largest
impediment to regulating Internet pharmacies located in the U.S. has proven to be the elusiveness of the
operators of such sites. The Act does require operators to disclose identifying information, but given the
anonymity provided by the Internet, the Act will not make it easier to track down operators who refuse to
provide identifying information. Nevertheless, the possibility of a $500,000 ﬁne may be suﬃcient to deter
most people from engaging in such activities. Even if the probability of being caught is low, the expected ﬁne
(i.e., probability of being caught multiplied by the magnitude of the applicable ﬁne) may be high enough to
deter such activities. Another virtue of the Internet Prescription Sales Act is that it addresses the problem
of lack of resources by federal actors. An additional allocation of funds to the FDA would enable the FDA
to identify and bring more actions against illegal Internet pharmacies to enforce existing laws.
Both bills proposed to enable state attorneys general to obtain nationwide injunctions against rogue Internet
pharmacies. Allowing nationwide injunctions will be crucial if states are to play a signiﬁcant role in regulating
Internet pharmacies in the future. Under the current regulatory regime, states are wasting resources by
engaging in duplicative investigations and prosecutions against out-of-state Internet pharmacies. If action
by one state attorney general could preclude an Internet pharmacy from operating or re-opening in other
states, this would allow states to allocate their limited resources more eﬃciently.
Although these proposals are all commendable in their attempts to regulated domestic Internet pharmacies,
they fall short in protecting consumers from rogue foreign Internet pharmacies. Neither bill oﬀers a practical
solution to the larger problem of foreign Internet pharmacies. The Internet Pharmacy Consumer Act does
permit the FDA to enjoin the transfer of funds traceable to illegal transactions, but such actions will be
28ineﬀectual given the ease with which such business can change the name and location of its operations. More
drastic legislation is needed if we want to protect consumers from the risk of counterfeit and substandard
drugs.
FDA Proposal: Ban All Mail Imports. Recently, the FDA has made a recommendation to the Secretary
of Health and Human Services (HHS) that Customs deny entry of all pharmaceuticals imported through
the mail and return them to the sender.105 The policy, however, would retain the current Personal Use
Policy, allowing a “minute percentage” of imports to enter for patients with serious diseases to import an
unapproved drug from a foreign country.106 To prevent this exception from rendering the general rule un-
administrable, the FDA would require such products to obtain pre-clearance by the FDA and require such
parcels to be clearly marked.107 To enable Customs to seize all incoming pharmaceuticals, Congress would
have to repeal the Drug Import Fairness Act, which requires the government to give notice and due process
to citizens whose packages are conﬁscated. According to William Hubbard, an FDA commissioner: “[w]e
can’t go through the process that we must now go to, which is to mail a letter to the recipient, receive a
response back, and go through that 2 million times.”108
The FDA proposal appears to be the only way to assure that the federal government can maintain some
level of control over the growth of foreign Internet pharmacies that oﬀer their products to U.S. citizens. The
policy would not completely eliminate the risk that counterfeit and unsafe drugs are entering the country.
Without an allocation of additional resources to U.S. Customs by Congress, Customs will still be unable to
x-ray or otherwise analyze every potential pharmaceutical import that passes through its facilities. Never-
theless, this program would be allow Customs to seize many more packages than under the current regime.
105Hearings 2001, supra note 25, at 46 (testimony of William Hubbard).
106Id. at 62.
107Id. at 137.
108Id. at 62.
29Additionally, a strict rule enforcing seizure if the products are caught will discourage many consumers from
ordering drugs from foreign Internet sites to begin with.
Unfortunately, the FDA proposal, standing alone, may be politically unfeasible because it will harm indi-
viduals who cannot aﬀord drugs in the United States and who have had to turn to foreign Internet markets.
These individuals may be willing to assume the risk of taking counterfeit drugs, since the alternative would
be forgoing any treatment at all. One counter argument is that the FDA’s proposal does not change the
FDA’s policy on physical imports. Consumers could still travel across the border to obtain lower-priced
drugs in Canada and Mexico, and these practices are safer since consumers actually visit the foreign phar-
macy and would be able to return to the store if there is a problem and the foreign government is able to
locate the operators. Of course, legislative action would be necessary to address the aﬀordability issues of
those who cannot even aﬀord to travel to obtain cheaper medications. A discussion of alternative methods of
dealing with this issue beyond the scope of this paper, it is important to point out that addressing Internet
pharmacies must be dealt with in tandem with healthcare aﬀordability.
Another problem with the FDA policy is that such an attempt to shut the United States borders to the
international pharmaceuticals trade could be deemed a World Trade Organization (WTO) violation. The
WTO Agreement on the Application of Sanitary and Phytosanitary Measures (SPS Agreement) requires that
measures that restrict trade for precautionary reasons must apply “only to the extent necessary to protect
human, animal or plant life or health,” be based on scientiﬁc principles, and not be maintained without
suﬃcient scientiﬁc evidence.109 The WTO has declared actions similar to a pharmaceutical ban to be in
violation of the SPS Agreement. For example, in the mid-1990’s, some European nations enacted legislation
which banned the importation of hormone-injected beef from the United States. The WTO declared the acts
discriminatory because there was a lack of scientiﬁc evidence that the hormones posed a substantial health
109Agreement on the Application of Sanitary and Phytosanitary Measures, art. 2.2, Apr. 15, 1995, Marrakesh Agreement
Establishing the World Trade Organization, Annex 1A, Results of the Uraguay Round of Multilateral Trade Negotiations,
vol. 1, 69, 70 (1994).
30risk.110 Surely the U.S. could generate scientiﬁc evidence that counterfeit or adulterated pharmaceuticals
pose a substantial health risk to U.S. consumers, however, a country harmed by a U.S. ban on imported
pharmaceuticals could argue that the ban is discriminatory and in violation of the SPS Agreement if that
country maintains stringent regulations over the quality of its pharmaceutical supply. If the WTO ﬁnds such
a policy to violate the SPS agreement, it could either require the U.S. to reduce trade barriers in other areas
or allow increased trade barriers by the complaining country against the U.S.111 Although this discussion
only presents a cursory review of the potential international trade issues, it is clear that these issues should
be addressed and considered in depth before any policy is adopted.
VII. Conclusion.
The borderless nature of the Internet has challenged and will continue to challenge the regulation of pharma-
ceuticals in the United States. The most diﬃcult problem has been addressing the problem of foreign based
Internet pharmacies and protecting consumers from the counterfeit, unsafe drugs that may be dispensed by
these companies. Enacting legislation to address foreign Internet pharmacies may take a long time due to
the need to balance the goals of (i) maintaining high standards for the drug supply in the U.S., (ii) ensuring
aﬀordability of pharmaceuticals to low-income individuals, and (iii) avoiding overly burdensome regulation
of e-commerce and the international marketplace. Perhaps in the meantime, the best approach is to try to
reduce consumer demand for such goods by implement public service campaigns to inform consumers as to
the dangers of ordering pharmaceuticals from foreign-based pharmacies. In addition to having an eﬀect on
consumer demand, these education campaigns may also be eﬀective in rallying the necessary congressional
support to address the problem directly, swiftly and comprehensively.
110Ambrose, Kathleen, Science and the WTO, 31 Law & Pol’y Int’l Bus 861 (2000).
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